Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Pharma Majors Bounce Back

      Posted AtFinancial Express

      NEW DELHI, AUG 2: Indian pharma majors, except Ranbaxy Laboratories Ltd, have bounced back with double digit profit growth in the quarter ending June as a result of improved performance across geographies. While Dr Reddy's saw net profits double, Sun, Cipla and Wockhardt's net improved 67%, 41% and 55% respectively. In the January-March quarter, all these companies, except Cipla, saw declining profits or losses due to various issues like value-added tax and MRP-based excise.
      For most companies, the boost in profits came as overseas sales, including US and Europe, improved. Also, total expenditure for most companies grew at a lesser rate than sales due to drive down of inventories. In the run-up to VAT, many wholesalers and dealers had reduced their inventory levels.

      For instance, Dr Reddy's - which posted a profit for the first time in 7 quarters - saw revenues from European markets improve 98% to Rs 57 crore and sale of branded drugs abroad rise 47% to Rs 116 crore. Cipla, too, saw a rise in overseas sales increase 40% to Rs 285 crore. On the other hand, Ranbaxy, which has seen US sales fall 11% this quarter, saw net profits down 48%.

      "Indian pharma companies are beginning to reap the rewards of the alliances they have been forming over the past two years. This spike in overseas sales has come because of their efforts at forward integration," said an industry analyst. Also, companies are working to enter into new geographies through alliances or acquisitions. Dr Reddy's is shoring up front-end presence in Russia and CIS, while Wockhardt is investing up to $100 million to widen its European distribution network.

      "Also, there is a typical spike in sales during the monsoon months especially in the anti-infectives category," added an analyst with an equity brokerage.

      However, all including the companies themselves, admit that outlook is not very rosy mainly due to fierce competition in overseas markets where generic drug prices are falling as much as 95% and innovators are employing tactics like "authorized generics" to discourage para-4 filings. Ranbaxy has lowered its earnings forecast for the year and Dr Reddy's too reiterated its statement of "this is a tough year."

      August 03, 2005


      Share this Article!

    Back to top^